Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sevelamer

Sanofi reception

Sanofi agrees €250m diabetes deal with AI firm Exscientia

The French pharma giant will pay royalties and contribute research funding

- PMLiVE

Teva drops laquinimod for most common form of MS after failed trial

CONCERTO study showed no disability progression improvements over placebo

- PMLiVE

Teva launches asthma social media campaign

Hopes awareness drive will improve inhaler use

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

- PMLiVE

Amgen sues Sanofi and Regeneron over eczema drug

Alleges patent infringement and seeks financial reparations

Deal Watch March 2017

Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up

- PMLiVE

Sanofi appoints Bill Sibold to lead its Genzyme business

He will succeed David Meeker, who is leaving in the firm in June

- PMLiVE

FDA approves Teva’s Huntington’s disease drug at second attempt

Austedo will treat fatal degenerative disorder chorea

- PMLiVE

Regeneron bags US approval for eczema drug Dupixent

Aims to balance affordability and rewarding innovation with the treatment's pricing

Sanofi to develop a mobile app for insulin patients

Will work with therapeutic companion software company Voluntis

- PMLiVE

NICE set to back Parsabiv for kidney disease complication

Draft guidance recommends Amgen treatment for secondary hyperparathyroidism

Sanofi reception

Sanofi adds to dupilumab evidence base as US approval nears

FDA to deliver verdict on atopic dermatitis drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links